Another oral antiviral treatment, but still far away from hepatitis B virus cure

키워드

참고문헌 (17)

1. Schweitzer A, "Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013", Lancet, 386, pp.1546~1555 (2015)
2. Tseng TC, "Elimination of hepatitis b: is it a mission possible?", BMC Med, 15, pp.53~ (2017)
3. Yim HJ, "Besifovir dipivoxil maleate 144-week treatment of chronic hepatitis B: an open-label extensional study of a phase 3 trial", Am J Gastroenterol, 115, pp.1217~1225 (2020)
4. Ahn SH, "Efficacy and safety of besifovir dipivoxil maleate compared with tenofovir disoproxil fumarate in treatment of chronic hepatitis B virus infection", Clin Gastroenterol Hepatol, 17, pp.1850~1859.e4 (2019)
5. Do Seon Song, "Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial", Clinical and Molecular Hepatology, 27(2), pp.346~359 (2021), 대한간학회[DOI]
6. Buti M, "Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial", Lancet Gastroenterol Hepatol, 1, pp.196~206 (2016)
7. Marcellin P, "Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study", Lancet, 381, pp.468~475 (2013)
8. Revill PA, "A global scientific strategy to cure hepatitis B", Lancet Gastroenterol Hepatol, 4, pp.545~558 (2019)
9. Takako Inoue, "Novel biomarkers for the management of chronic hepatitis B", Clinical and Molecular Hepatology, 26(3), pp.261~279 (2020), 대한간학회[DOI]
10. Di Bisceglie AM, "Determination of hepatitis B phenotype using biochemical and serological markers", J Viral Hepat, 24, pp.320~329 (2017)
11. Bonacci M, "Anti-viral therapy can be delayed or avoided in a significant proportion of HBeAg-negative Caucasian patients in the grey zone", Aliment Pharmacol Ther, 47, pp.1397~1408 (2018)
12. Lee HW, "Progression of untreated minimally active chronic HBV infection compared to inactive infection", Clin Gastroenterol Hepatol, 17, pp.2808~2810.e2 (2019)
13. Tseng TC, "High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load", Gastroenterology, 142, pp.1140~1149.e3 (2012)
14. Tseng TC, "High level of hepatitis B core-related antigen associated with increased risk of hepatocellular carcinoma in patients with chronic HBV infection of intermediate viral load", Gastroenterology, 157, pp.1518~1529.e3 (2019)
15. Papatheodoridis G, "PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy", J Hepatol, 64, pp.800~806 (2016)
16. Tseng TC, "Baseline Mac-2 binding protein glycosylation isomer level stratifies risks of hepatocellular carcinoma in chronic hepatitis B patients with oral antiviral therapy", Liver Cancer, 9, pp.207~220 (2020)
17. Tseng TC, "One-year fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment", Hepatol Int, 15, pp.105~113 (2021)

관련 논문AI추천